Cargando…

Allopurinol Lowers Serum Urate but Does Not Reduce Oxidative Stress in CKD

Xanthine oxidase (XO) contributes to oxidative stress and vascular disease. Hyperuricemia and gout are common in patients with chronic kidney disease (CKD), a population at increased risk of vascular disease. We evaluated effects of allopurinol on serum XO activity and metabolome of CKD patients who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Mingyao, Hines, Nicole, Scerbo, Diego, Buchanan, Jane, Wu, Chaorong, Ten Eyck, Patrick, Zepeda-Orozco, Diana, Taylor, Eric B., Jalal, Diana I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312025/ https://www.ncbi.nlm.nih.gov/pubmed/35883787 http://dx.doi.org/10.3390/antiox11071297

Ejemplares similares

Uric Acid Lowering and Biomarkers of Kidney Damage in CKD Stage 3: A Post Hoc Analysis of a Randomized Clinical Trial
por: Perrenoud, Loni, et al.
Publicado: (2020)

Persistence with urate‐lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions
por: Coleshill, Matthew J., et al.
Publicado: (2022)

Impact of allopurinol use on urate concentration and cardiovascular outcome
por: Wei, Li, et al.
Publicado: (2011)

Detection of pro angiogenic and inflammatory biomarkers in patients with CKD
por: Jalal, Diana, et al.
Publicado: (2021)

Hyperuricaemia, gout and allopurinol in the CKD Queensland registry
por: Jeyaruban, A., et al.
Publicado: (2021)

Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress
por: George, Jacob, et al.
Publicado: (2009)

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A, et al.
Publicado: (2015)

Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate‐Lowering Response—In Search of a Minimum Effective Oxypurinol Concentration
por: Stamp, Lisa K., et al.
Publicado: (2019)

How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose
por: Stamp, Lisa K., et al.
Publicado: (2018)

Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A., et al.
Publicado: (2015)

Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study
por: Rodríguez-Martín, Sara, et al.
Publicado: (2019)

Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
por: Dalbeth, Nicola, et al.
Publicado: (2018)

Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study
por: Søltoft Larsen, Kasper, et al.
Publicado: (2016)

An Open‐Label Dose‐Finding Study of Allopurinol to Target Defined Reduction in Urate Levels in Hemodialysis Patients
por: Rutherford, Elaine, et al.
Publicado: (2017)

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study
por: Kataoka, Hiroshi, et al.
Publicado: (2022)

Caring for Australians and New Zealanders With Kidney Impairment Guidelines: Rapid Development of Urate Lowering Therapy Guidelines for People With CKD
por: Stanley, Isabelle Kitty, et al.
Publicado: (2022)

Evaluating the feasibility of a pharmacist-guided patient-driven intervention to improve blood pressure control in patients with CKD
por: Hopley, Charles, et al.
Publicado: (2019)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Mitochondrial Oxidative Metabolism: An Emerging Therapeutic Target to Improve CKD Outcomes
por: Mapuskar, Kranti A., et al.
Publicado: (2023)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial
por: Stamp, Lisa K., et al.
Publicado: (2017)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia
por: Jalalzadeh, Mojgan, et al.
Publicado: (2012)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019)

Factors associated with initiation and persistence of urate-lowering therapy
por: Dehlin, Mats, et al.
Publicado: (2017)

Review of Urate-Lowering Therapeutics: From the Past to the Future
por: Jenkins, Christopher, et al.
Publicado: (2022)

Commentary on: The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia
por: Nasri, Hamid
Publicado: (2013)

Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial
por: Saag, Kenneth G., et al.
Publicado: (2022)

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
por: Tabi-Amponsah, Adwoa Dansoa, et al.
Publicado: (2023)

Does Serum Urate Change as Parkinson’s Disease Progresses?
por: Hasimoglu, Yasemin G., et al.
Publicado: (2020)

Allopurinol induced erythroderma
por: Sharma, Geeta, et al.
Publicado: (2013)

Allopurinol: Sorrow to the marrow
por: Raaju, UR, et al.
Publicado: (2020)

Allopurinol hypersensitivity syndrome
por: Yaseen, Wid, et al.
Publicado: (2023)

The Effects of Lowering Uric Acid Levels Using Allopurinol on Components of Metabolic Syndrome
por: Heimbach, Esther J., et al.
Publicado: (2012)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
por: Chen, Mo, et al.
Publicado: (2020)

Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial
por: Andrews, Emily S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7or0afbf2qm7kaf0ke17f2p32f